SummitTX Capital’s AbbVie ABBV Stock Holding History

SummitTX Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$942K	Buy	3,743 +1,244	+50%	+$268K	0.02%	472
2026 Q1	$544K	Buy	+2,499	New	+$554K	0.02%	551
2025 Q4	–	Sell	-7,954	Closed	-$1.84M	–	674
2025 Q3	$1.84M	Sell	7,954 -3,967	-33%	-$808K	0.08%	271
2025 Q2	$2.21M	Buy	+11,921	New	+$2.22M	0.1%	234

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

SummitTX Capital's ABBV Position: Q2 2026 in Review

SummitTX Capital increased its AbbVie (ABBV) stake by 50% in Q2 2026, buying an estimated $268K and bringing the position to 3,743 shares worth $942K. The position accounts for 0.02% of the portfolio, ranked #472.

SummitTX Capital first reported a position in ABBV in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.21M in Q2 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

SummitTX Capital held 3,743 shares of AbbVie worth $942K as of Q2 2026.
SummitTX Capital bought 1,244 AbbVie shares in Q2 2026, an estimated $268K.
AbbVie made up 0.02% of SummitTX Capital's portfolio in Q2 2026, its #472 holding.
SummitTX Capital first reported a position in AbbVie in Q2 2025 and has held it in 4 quarters since.
SummitTX Capital's AbbVie position peaked at $2.21M in Q2 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.